AVIR Atea Pharmaceuticals

Atea Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

Atea Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced that Jean-Pierre Sommadossi, Ph.D., Founder, Chairman and Chief Executive Officer of Atea will present a corporate overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 2:30 p.m. ET.

A live webcast of the presentation will be available and on the Company’s website at . A replay of the webcast will be available for 90 days following the presentation.  

About Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). For more information, please visit .

Contacts

Jonae Barnes

SVP, Investor Relations and Corporate Communications

617-818-2985

Will O’Connor

Stern Investor Relations

212-362-1200



EN
26/05/2021

Underlying

AVIRAtea Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Atea Pharmaceuticals

 PRESS RELEASE
Free
AVIR Atea Pharmaceut...

Atea Pharmaceuticals to Present New Data Supporting Combination of Bem...

Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025 BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that new data will be presented supporting the combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor and ru...

October 7, 2025 1 EN
 PRESS RELEASE
Free
AVIR Atea Pharmaceut...

Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Glob...

Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that members of the Atea management team will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 1:05 p.m. ET in New York, NY. A live webcast of the presentatio...

September 2, 2025 1 EN
 PRESS RELEASE
Free
AVIR Atea Pharmaceut...

Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and...

Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Patient Enrollment Advances in Global Phase 3 Program for Treatment of HCV  Four Scientific Posters Presented at EASL, Including Final Results from Phase 2 Study of Bemnifosbuvir/Ruzasvir Regimen Confirming 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration Regimen of Bemnifosbuvir/Ruzasvir has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect BOSTO...

August 7, 2025 1 EN
 PRESS RELEASE
Free
AVIR Atea Pharmaceut...

Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and...

Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025 BOSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, August 7, 2025, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2025, and to provide a business update. ...

July 31, 2025 1 EN
 PRESS RELEASE
Free
AVIR Atea Pharmaceut...

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3...

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect HCV Infection Remains a Significant Global Health Burden, with Approximately 50 Million People Infected, Including up to 4 Million in US...

June 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch